IPCA asks USFDA to clarify on Hydroxychloroquine risk

Hydroxychloroquine, besides being administered as an anti-malarial
drug, is also used as a chronic therapy by patients suffering from
auto immune diseases such as RA and Lupus. In the recent months the
drug has been used in several countries including India and US in the
treatment of critically ill Covid-19 patients.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ipca-asks-usfda-to-clarify-on-hydroxychloroquine-risk/articleshow/75462945.cms

Comments

Popular posts from this blog

The Scroll and the Revolution: The Dilemmas of Writing about the Jews of Cuba

The Right Tool for the Job: Foreign Policy Effectiveness and Nuclear Proliferation

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply